RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T18:53:00Z
IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024
Tue 15 Oct 24, 08:15 PMJerome Dodson's Strategic Moves in Q3 2024 Highlight JB Hunt Transport Services Inc
Thu 10 Oct 24, 11:02 PMHere's Why You Should Retain IQVIA Holdings Shares Now
Fri 04 Oct 24, 03:50 PMIQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™
Wed 02 Oct 24, 01:00 PMPossible Bearish Signals With IQVIA Holdings Insiders Disposing Stock
Mon 30 Sep 24, 11:00 AMIQVIA Holdings Inc. (IQV): Hedge Funds Are Bullish On This Trending AI Stock Right Now
Wed 25 Sep 24, 12:26 PMIQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award
Thu 19 Sep 24, 01:00 PMIQV Gains From Clinical Development Capabilities Amid Low Liquidity
Tue 17 Sep 24, 03:31 PMWhy IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Tue 17 Sep 24, 01:40 PMIQVIA Holdings Inc. (NYSE:IQV): A Non-Tech Stock With Long-Term Investment Potential
Tue 17 Sep 24, 05:12 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 1363.00M | 1128.00M | 373.00M | 352.00M | 328.00M |
| Minority interest | 0.00000M | -5.00000M | 29.00M | 36.00M | 25.00M |
| Net income | 1091.00M | 966.00M | 279.00M | 191.00M | 259.00M |
| Selling general administrative | 2071.00M | 1964.00M | 1789.00M | 1734.00M | 1716.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 5028.00M | 4641.00M | 3859.00M | 3788.00M | 3666.00M |
| Reconciled depreciation | 1130.00M | 1264.00M | 1287.00M | 1202.00M | 1141.00M |
| Ebit | 1799.00M | 1393.00M | 731.00M | 777.00M | 812.00M |
| Ebitda | 2937.00M | 2813.00M | 2141.00M | 2100.00M | 1953.00M |
| Depreciation and amortization | 1138.00M | 1420.00M | 1410.00M | 1323.00M | 1141.00M |
| Non operating income net other | -32.00000M | 116.00M | 65.00M | 13.00M | 16.00M |
| Operating income | 1799.00M | 1393.00M | 731.00M | 777.00M | 741.00M |
| Other operating expenses | 12583.00M | 12461.00M | 10576.00M | 10236.00M | 9603.00M |
| Interest expense | 416.00M | 375.00M | 416.00M | 447.00M | 414.00M |
| Tax provision | 260.00M | 163.00M | 72.00M | 116.00M | 59.00M |
| Interest income | 403.00M | 6.00M | 6.00M | 9.00M | 8.00M |
| Net interest income | -403.00000M | -369.00000M | -410.00000M | -438.00000M | -406.00000M |
| Extraordinary items | - | - | - | 0.00000M | 35.00M |
| Non recurring | 28.00M | 20.00M | 52.00M | 75.00M | 68.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 260.00M | 163.00M | 72.00M | 116.00M | 59.00M |
| Total revenue | 14410.00M | 13874.00M | 11359.00M | 11088.00M | 10412.00M |
| Total operating expenses | 3201.00M | 3228.00M | 3076.00M | 2936.00M | 2857.00M |
| Cost of revenue | 9382.00M | 9233.00M | 7500.00M | 7300.00M | 6746.00M |
| Total other income expense net | -436.00000M | -265.00000M | -358.00000M | -425.00000M | -75.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1091.00M | 971.00M | 301.00M | 236.00M | 269.00M |
| Net income applicable to common shares | 1091.00M | 966.00M | 279.00M | 191.00M | 259.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 25337.00M | 24689.00M | 24564.00M | 23251.00M | 22549.00M |
| Intangible assets | 4820.00M | 4943.00M | 5205.00M | 5514.00M | 5951.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 561.00M | 521.00M | 563.00M | 451.00M | 322.00M |
| Total liab | 19572.00M | 18647.00M | 18284.00M | 16988.00M | 15595.00M |
| Total stockholder equity | 5765.00M | 6042.00M | 6001.00M | 6003.00M | 6714.00M |
| Deferred long term liab | 464.00M | 410.00M | 338.00M | 646.00M | 736.00M |
| Other current liab | 313.00M | 344.00M | 344.00M | 319.00M | 1990.00M |
| Common stock | 10898.00M | 10777.00M | 11095.00M | 11049.00M | 10901.00M |
| Capital stock | 10898.00M | 10777.00M | 11095.00M | 11049.00M | 10901.00M |
| Retained earnings | 3334.00M | 2243.00M | 1277.00M | 998.00M | 807.00M |
| Other liab | 911.00M | 1059.00M | 971.00M | 1072.00M | 1140.00M |
| Good will | 13921.00M | 13301.00M | 12654.00M | 12159.00M | 11800.00M |
| Other assets | 590.00M | 615.00M | 1133.00M | 346.00M | 344.00M |
| Cash | 1216.00M | 1366.00M | 1814.00M | 837.00M | 891.00M |
| Cash and equivalents | 1216.00M | 1366.00M | 1814.00M | 837.00M | 891.00M |
| Total current liabilities | 5578.00M | 5241.00M | 4558.00M | 3945.00M | 3534.00M |
| Current deferred revenue | 1797.00M | 1825.00M | 1252.00M | 1014.00M | 1007.00M |
| Net debt | 11795.00M | 11072.00M | 11090.00M | 11204.00M | 10116.00M |
| Short term debt | 152.00M | 91.00M | 149.00M | 100.00M | 100.00M |
| Short long term debt | 152.00M | 91.00M | 149.00M | 100.00M | 100.00M |
| Short long term debt total | 13011.00M | 12438.00M | 12904.00M | 12041.00M | 11007.00M |
| Other stockholder equity | -7740.00000M | -6572.00000M | -6166.00000M | -5733.00000M | -4770.00000M |
| Property plant equipment | 863.00M | 903.00M | 482.00M | 458.00M | 434.00M |
| Total current assets | 4981.00M | 4763.00M | 5090.00M | 4126.00M | 3874.00M |
| Long term investments | 162.00M | 164.00M | 84.00M | 87.00M | 142.00M |
| Net tangible assets | -12976.00000M | -12202.00000M | -11858.00000M | -11670.00000M | -11037.00000M |
| Short term investments | 93.00M | 111.00M | 88.00M | 62.00M | 47.00M |
| Net receivables | 2960.00M | 2609.00M | 2466.00M | 2638.00M | 2463.00M |
| Long term debt | 12595.00M | 12034.00M | 12384.00M | 11545.00M | 10907.00M |
| Inventory | 151.00M | 156.00M | 159.00M | 138.00M | 151.00M |
| Accounts payable | 3316.00M | 2981.00M | 2813.00M | 2512.00M | 437.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 279.00M | 260.00M | 240.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -727.00000M | -406.00000M | -205.00000M | -311.00000M | -224.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 10898.00M | 10777.00M | 11095.00M | 11049.00M | 10901.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 3334.00M | 2243.00M | 1277.00M | 998.00M | 807.00M |
| Treasury stock | - | -6572.00000M | -6166.00000M | -5733.00000M | -4770.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 472.00M | 491.00M | 386.00M | 227.00M | 239.00M |
| Deferred long term asset charges | - | - | - | 119.00M | 109.00M |
| Non current assets total | 20356.00M | 19926.00M | 19474.00M | 19125.00M | 18675.00M |
| Capital lease obligations | 264.00M | 313.00M | 371.00M | 396.00M | - |
| Long term debt total | 12595.00M | 12034.00M | 12384.00M | 11545.00M | 10907.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2006.00000M | -10.00000M | -2.00000M | -22.00000M | -23.00000M |
| Change to liabilities | 299.00M | 835.00M | 170.00M | 235.00M | 250.00M |
| Total cashflows from investing activities | -2006.00000M | -2103.00000M | -796.00000M | -1190.00000M | -810.00000M |
| Net borrowings | 936.00M | 70.00M | 309.00M | 700.00M | 993.00M |
| Total cash from financing activities | -329.00000M | -1235.00000M | -217.00000M | -276.00000M | -452.00000M |
| Change to operating activities | 7.00M | -15.00000M | -146.00000M | -92.00000M | -66.00000M |
| Net income | 1091.00M | 971.00M | 308.00M | 227.00M | 284.00M |
| Change in cash | -150.00000M | -448.00000M | 977.00M | -54.00000M | -68.00000M |
| Begin period cash flow | 1366.00M | 1814.00M | 837.00M | 891.00M | 959.00M |
| End period cash flow | 1216.00M | 1366.00M | 1814.00M | 837.00M | 891.00M |
| Total cash from operating activities | 2260.00M | 2942.00M | 1959.00M | 1417.00M | 1254.00M |
| Issuance of capital stock | - | - | - | - | 15.00M |
| Depreciation | 1130.00M | 1264.00M | 1287.00M | 1202.00M | 1141.00M |
| Other cashflows from investing activities | -1332.00000M | 5.00M | -178.00000M | -586.00000M | -328.00000M |
| Dividends paid | - | - | 13.00M | 18.00M | 4076.00M |
| Change to inventory | - | -17.00000M | -229.00000M | -116.00000M | -184.00000M |
| Change to account receivables | -421.00000M | -138.00000M | 255.00M | -124.00000M | -297.00000M |
| Sale purchase of stock | -1168.00000M | -406.00000M | -447.00000M | -949.00000M | -1405.00000M |
| Other cashflows from financing activities | 3498.00M | 1862.00M | 2729.00M | 4348.00M | 8075.00M |
| Change to netincome | 108.00M | 15.00M | -113.00000M | -44.00000M | -76.00000M |
| Capital expenditures | 674.00M | 640.00M | 616.00M | 582.00M | 459.00M |
| Change receivables | -421.00000M | -138.00000M | 255.00M | -122.00000M | -297.00000M |
| Cash flows other operating | 38.00M | 576.00M | 34.00M | -94.00000M | -59.00000M |
| Exchange rate changes | - | - | - | - | -60.00000M |
| Cash and cash equivalents changes | -75.00000M | -396.00000M | 946.00M | -49.00000M | -68.00000M |
| Change in working capital | -84.00000M | 680.00M | 459.00M | 19.00M | -106.00000M |
| Stock based compensation | 194.00M | 170.00M | 95.00M | 146.00M | 113.00M |
| Other non cash items | 44.00M | -5.00000M | -14.00000M | -20.00000M | -1.00000M |
| Free cash flow | 1586.00M | 2302.00M | 1343.00M | 835.00M | 795.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings Inc |
-0.225 0.12% | 190.75 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
| TMO Thermo Fisher Scientific Inc |
2.81 0.54% | 518.99 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.38 0.17% | 227.92 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-0.4 0.10% | 410.36 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| A Agilent Technologies Inc |
0.86 0.65% | 133.87 | 31.97 | 25.84 | 6.23 | 6.96 | 6.62 | 23.01 |
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
4820 Emperor boulevard, Durham, NC, United States, 27703
| Name | Title | Year Born |
|---|---|---|
| Ms. Keriann Cherofsky | Sr. VP, Corp. Controller & Principal Accounting Officer | 1984 |
| Mr. Ari Bousbib | Chairman, Pres & CEO | 1961 |
| Mr. Ronald E. Bruehlman | Exec. VP & CFO | 1961 |
| Mr. Eric M. Sherbet | Exec. VP, Gen. Counsel & Sec. | 1964 |
| Mr. Kevin C. Knightly | Pres of Corp. Strategy & Enterprise Networks | 1961 |
| Dr. Jeffrey A. Spaeder | Sr. VP, Global Chief Medical & Scientific Officer | NA |
| Mr. Karl Guenault | Sr. VP & Chief Information Officer | NA |
| Andrew Markwick | Sr. VP of Investor Relations | NA |
| Mr. Nicholas Childs | Sr. VP, Investor Relations & Corp. Communications | NA |
| Ms. Trudy Stein | Chief HR Officer & Exec. VP | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...